ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
Subclavian chronic total occlusion angioplasty facilitates cardiac implantable electronic device upgrades: A single-center case series.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubclavian venous occlusion is a frequent complication of transvenous cardiac implantable electronic device (CIED) implantation, with reported incidences exceeding 30%. Although often asymptomatic, chronic total occlusion (CTO) creates a major technical barrier during device revision, particularly for cardiac resynchronization therapy (CRT) upgrades. Conventional strategies such as lead extraction or contralateral tunneling may increase procedural risk or compromise future vascular access. Subclavian CTO venoplasty is a minimally invasive alternative to re-establish ipsilateral access.
methodsWe describe a single-center series of six patients (ages 62–78 years) who underwent percutaneous subclavian, axillary, or brachiocephalic venoplasty to facilitate CIED upgrade or lead revision. Our approach favored ipsilateral upper-extremity access (typically basilic vein) with a 0.018-inch platform using polymer-jacketed guidewires and microcatheters for CTO crossing. Serial balloon angioplasty (4.0–10.0 mm; 40–80 mm length range) was performed using stepwise inflation (nominal pressure with escalation as needed up to rated burst pressure per device specifications) to restore venous patency.
resultsTechnical success was achieved in all six cases (100%), enabling four CRT implantations, one left bundle branch area pacing (LBBAP) implant, and one dual-chamber lead revision. No major intraprocedural complications occurred; one patient developed a self-resolving chest wall hematoma. Procedure time ranged from 116 to 240 min. Among CRT recipients, QRS duration narrowed (mean reduction 45 ± 18 ms). Follow-up (2–12 months) demonstrated stable lead parameters and no clinical evidence of recurrent occlusion.
conclusionIn this small series, subclavian/central venous CTO venoplasty using a brachial-first, 0.018-inch CTO-oriented strategy was feasible and enabled successful ipsilateral CIED revision while preserving vascular access. Larger studies are needed to better define the success rate and safety relative to the extraction or subclavian/device pocket access only approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.